TAGline

ICC's Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That? "It's ddC Monotherapy All Over Again" A hastily organized meeting of the newly formed Inter-Company Collaborative (ICC) was convened April 26 at the…

Accelerated Approval Guidelines Expedite Bristol's Launch of New Nucleoside -- In the Absence of Any Proof That It Works Specter of Fast Track Review Haunts Those Who Spawned It "FDA Panel Recommends Drug Despite Incomplete Data." So read the New…

KS Proves Formidable Foe As Angiogenesis Inhibitors and Stealth Chemotherapy Fall Short of Expectations Pregnant Mice the Key? Michael Marco recently returned from a transcontinental tour of KS research laboratories. While his official report is not due out for another…

One Company's Search for an Effective Antiviral Contrasts Another's Scramble for the Easy Money The Perils & Pains of Integrity Early on a rainy Monday morning, Merck scientists Emilio Emini and John Ryan assembled overheads and flip charts before a…

Study After Study, Antiretroviral Analyses Confound More Than They Clarify Lamenting the Naked Emperor First there was Concorde, the now notorious Anglo-French study which last summer sent shock waves across the Atlantic as it cast doubt on the wisdom of…

By Mark Harrington A cure for HIV is possible: one man, the so-called Berlin patient, has already been cured of chronic HIV infection with an immune system transplant with cells genetically resistant to HIV. After four years, the man remains…

By Richard Jefferys The research effort to discover a cure for HIV infection continues to gain momentum, with several important developments having occurred since the last issue of TAGline. In July, the National Institute of Allergy and Infectious Diseases (NIAID)…